CA2892756C - Engineered monomeric antibody fragments - Google Patents

Engineered monomeric antibody fragments Download PDF

Info

Publication number
CA2892756C
CA2892756C CA2892756A CA2892756A CA2892756C CA 2892756 C CA2892756 C CA 2892756C CA 2892756 A CA2892756 A CA 2892756A CA 2892756 A CA2892756 A CA 2892756A CA 2892756 C CA2892756 C CA 2892756C
Authority
CA
Canada
Prior art keywords
polypeptide
domain
engineered
amino acid
monomeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2892756A
Other languages
English (en)
French (fr)
Other versions
CA2892756A1 (en
Inventor
Weili DUAN
Ronald W. Kriz
Ishino TETSUYA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CA2892756A1 publication Critical patent/CA2892756A1/en
Application granted granted Critical
Publication of CA2892756C publication Critical patent/CA2892756C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2892756A 2012-12-07 2013-11-25 Engineered monomeric antibody fragments Active CA2892756C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261734841P 2012-12-07 2012-12-07
US61/734,841 2012-12-07
PCT/IB2013/060384 WO2014087299A1 (en) 2012-12-07 2013-11-25 Engineered monomeric antibody fragments

Publications (2)

Publication Number Publication Date
CA2892756A1 CA2892756A1 (en) 2014-06-12
CA2892756C true CA2892756C (en) 2020-04-14

Family

ID=50001048

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2892756A Active CA2892756C (en) 2012-12-07 2013-11-25 Engineered monomeric antibody fragments

Country Status (6)

Country Link
US (1) US10233229B2 (https=)
EP (1) EP2928917B1 (https=)
JP (1) JP6396313B2 (https=)
CA (1) CA2892756C (https=)
ES (1) ES2664095T3 (https=)
WO (1) WO2014087299A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015074063A1 (en) * 2013-11-18 2015-05-21 University Of Maryland, Baltimore Hyper-glycosylated antibodies with selective fc receptor binding
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
EA201892249A1 (ru) 2016-04-04 2019-05-31 Шайр Хьюман Дженетик Терапиз, Инк. Конъюгированный ингибитор c1-эстеразы и пути его применения
JP7556687B2 (ja) 2017-02-24 2024-09-26 中外製薬株式会社 薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法
WO2019023097A1 (en) * 2017-07-26 2019-01-31 Smet Pharmaceutical Inc ASYMMETRIC BISPECIFIC ANTIBODIES AND THEIR USE
WO2020221450A1 (en) * 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies and methods for treatment of influenza a infection

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
KR100545720B1 (ko) * 2004-05-31 2006-01-24 메덱스젠 주식회사 당화된 면역글로불린 및 이를 포함하는 면역접합체
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US20110045007A1 (en) 2007-05-31 2011-02-24 Genmab A/S Fusion or linked proteins with extended half life
CA2766166A1 (en) 2009-07-08 2011-01-13 Amgen Inc. Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering
US20120276092A1 (en) * 2009-10-29 2012-11-01 Jinquan Luo Antibody Glycosylation Variants
ES2688978T3 (es) 2009-11-23 2018-11-07 Amgen Inc. Anticuerpo monomérico Fc

Also Published As

Publication number Publication date
ES2664095T3 (es) 2018-04-18
US20150322135A1 (en) 2015-11-12
CA2892756A1 (en) 2014-06-12
JP2016505559A (ja) 2016-02-25
JP6396313B2 (ja) 2018-09-26
EP2928917A1 (en) 2015-10-14
EP2928917B1 (en) 2018-02-28
WO2014087299A9 (en) 2015-08-27
US10233229B2 (en) 2019-03-19
WO2014087299A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
CN109705218B (zh) Asgpr抗体及其用途
CA2892756C (en) Engineered monomeric antibody fragments
AU2017207318B2 (en) Multivalent and multispecific OX40-binding fusion proteins
TW202313684A (zh) 抗ｃｃｒ８抗體及其用途
AU2017385274B2 (en) Fusion protein including BDNF
TWI839050B (zh) 抗trem-1抗體及其用途
CN110573528B (zh) 针对共刺激性tnf受体的双特异性抗原结合分子
CN111819198A (zh) 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA)
KR20160044060A (ko) 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
WO2016109415A1 (en) Anti-cd47 antibodies and uses thereof
CN110642952B (zh) 抗her3抗体、其制法及其应用
KR20140019385A (ko) 이중특이성 및 단일특이성, 비대칭성 항체 및 이의 제조방법
CN115956087B (zh) 抗-pd-1抗体
KR20230131236A (ko) 항-pd-l1 항체 및 이의 융합 단백질
CN116472288A (zh) 抗体Fc变体
US20250333542A1 (en) Interferon gamma variants and antigen binding molecules comprising these
AU2023387113A1 (en) Method for producing protein
HK40007646A (en) Asgpr antibodies and uses thereof
HK40007646B (en) Asgpr antibodies and uses thereof
HK40040223A (en) Anti-trem-1 antibodies and uses thereof
CN117242096A (zh) 结合psma和cd3的异二聚体双特异性抗体
CN116981687A (zh) 针对甲型流感病毒的抗体
HK40019153B (en) Bispecific antigen binding molecule for a costimulatory tnf receptor
HK40019153A (en) Bispecific antigen binding molecule for a costimulatory tnf receptor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150527

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250527

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251106